AQR Capital Management
CSTL icon

AQR Capital Management’s Castle Biosciences CSTL Stock Holding History

AQR Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.97M Buy
166,567
+101,687
+157% +$2.26M ﹤0.01% 2150
2026
Q1 		$1.59M Buy
64,880
+999
+2% +$32.7K ﹤0.01% 2500
2025
Q4 		$2.48M Buy
63,881
+13,039
+26% +$420K ﹤0.01% 2003
2025
Q3 		$1.16M Buy
50,842
+1,612
+3% +$32.7K ﹤0.01% 2342
2025
Q2 		$1.01M Sell
49,230
-87,792
-64% -$1.63M ﹤0.01% 2204
2025
Q1 		$2.74M Buy
137,022
+115,907
+549% +$2.87M ﹤0.01% 1438
2024
Q4 		$563K Buy
+21,115
New +$643K ﹤0.01% 2187
2024
Q2 		– Sell
-22,795
Closed -$505K – 2615
2024
Q1 		$505K Buy
22,795
+8,592
+60% +$187K ﹤0.01% 1954
2023
Q4 		$307K Sell
14,203
-240
-2% -$4.22K ﹤0.01% 2057
2023
Q3 		$244K Buy
+14,443
New +$253K ﹤0.01% 2080
2021
Q2 		– Sell
-6,381
Closed -$437K – 2239
2021
Q1 		$437K Sell
6,381
-4,446
-41% -$334K ﹤0.01% 1886
2020
Q4 		$727K Buy
+10,827
New +$587K ﹤0.01% 1644

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management's CSTL Position: Q2 2026 in Review

AQR Capital Management increased its Castle Biosciences (CSTL) stake by 157% in Q2 2026, buying an estimated $2.26M and bringing the position to 166,567 shares worth $3.97M. The position accounts for ﹤0.01% of the portfolio, ranked #2150.

AQR Capital Management first reported a position in CSTL in Q4 2020 and has held it in 12 quarters since. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • AQR Capital Management held 166,567 shares of Castle Biosciences worth $3.97M as of Q2 2026.
  • AQR Capital Management bought 101,687 Castle Biosciences shares in Q2 2026, an estimated $2.26M.
  • Castle Biosciences made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #2150 holding.
  • AQR Capital Management first reported a position in Castle Biosciences in Q4 2020 and has held it in 12 quarters since.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.